Overview

Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Multi-center, single-arm Phase 1b study designed to evaluate safety and tolerability of ARQ 197 in cirrhotic patients with HCC.
Phase:
Phase 1
Details
Lead Sponsor:
ArQule
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)